


Norway

Factor VIII per capita compared to other countries

This country fact sheet accompanies the EHC heat map and gives you further information on the country's progress over the various EHC surveys.

Here, you will see how the FVIII international units provision has evolved and compares to other countries. You will also find the same parameters as in the heat map.



Change since previous survey: ▲ Improvement ▼ Decline

		2009	2012	2015	2018
International units per capita	Factor VIII	4.19	▲ 5.63	▲ 6.46	▲ 6.73
	Factor IX	0.00	▲ 0.00	▲ 0.54	▲ 0.59
Organisation of care	Comprehensive Care Centres (CCC's)	Yes	Yes	Yes	Yes
	Haemophilia Treatment Centres	No	No	No	No
	National Haemophilia Council or Co-ordinating Group			No	▲ Yes
	Number of groups in decision-making on haemophilia care	0	0	▲ 3	3
	Number of groups choosing haemophilia treatment products	0	0	▲ 3	3
	National Tender for procurement of factor concentrates	Yes	Yes	Yes	Yes
Treatment regimens	Home Treatment	Yes	Yes	Yes	Yes
	% of people with haemophilia using home treatment	76-100%	76-100%	76-100%	76-100%
	Treatment delivered to the patient's home	Some	Some	Some	Unknown
	Prophylaxis treatment availability	Yes	Yes	Yes	Yes
	Children currently on prophylaxis (%)	76-100%	76-100%	76-100%	76-100%
	Adults currently on prophylaxis (%)	51-75%	51-75%	▲ 76-100%	76-100%
Access to specialist services	Access to ITI (% of people with inhibitors)	76-99%	76-99%	▲ 100%	100%
Access to specialist services	Emergency medicine and acute surgery			Yes	Yes
	Paediatrics			Yes	Yes
	Infectious disease specialists (especially HIV)			Yes	Yes
	Hepatology			Yes	Yes
	Rheumatology			Yes	Yes
	Orthopaedics			Yes	Yes
	Physiotherapy			Yes	Yes
	Dentistry			Yes	Yes
	Obstetrics and Gynaecology			Yes	▼ Never
	Genetics			Yes	Yes
	Social and psychological support			Yes	Yes
	Pain management			Yes	▼ Sometimes
General surgery			Yes	Yes	
Urology			Yes	Yes	
Share of Expected Bleeding Disorder Prevalence	Haemophilia A	62%		66%	▼ 62%
	Haemophilia B	66%		63%	▼ 56%
	von Willebrand Disease	18%		17%	▼ 11%
Haemophilia replacement therapy	Plasma-derived factor concentrate	Always	Always	▼ Rarely	Rarely
	Recombinant factor concentrate	Always	Always	Always	Always
	Plasma	Never	Never	Never	Never
	Cryoprecipitate	Never	Never	Never	Never
VWD replacement therapy	Plasma-derived factor concentrate			Always	Always
	DDAVP			Always	Always
	Plasma			Never	Never
	Cryoprecipitate			Never	Never